mometasone furoate + levocabastine hcl

Mometasone furoate + levocabastine hcl is a combination drug comprising an intranasal corticosteroid (mometasone furoate) and an intranasal antihistamine (levocabastine hydrochloride). - **Mometasone furoate** is a synthetic glucocorticoid that acts primarily as an anti-inflammatory and anti-allergic agent. It inhibits multiple inflammatory cytokines, reduces edema, and suppresses mediator release from mast cells and eosinophils. - **Levocabastine hcl** is a selective histamine H1 receptor antagonist (antihistamine), preventing histamine-induced symptoms such as nasal itching and rhinorrhea. This combination is primarily indicated for the treatment of moderate to severe allergic rhinitis, including conditions such as Japanese cedar pollinosis. Clinical trials have shown the combination provides superior control of nasal and ocular symptoms compared to corticosteroid monotherapy, decreases the need for rescue medications, and is well-tolerated[1][4]. The mechanism of action is the combined blockade of histamine-mediated allergic responses and reduction of inflammation in nasal tissues, offering additive or synergistic symptomatic control.

Other names

CKD-342CKD342CKD 342